ClinicaliQ Trial Snapshot
- ALTO-100 in Bipolar Disorder With Depression (BD-D) — Recruiting • Phase II • Mental Health / Psychiatry • NCT06656416.
- ALTO-100 tested against placebo for treating depression in bipolar disorder patients already on mood stabilizers or antipsychotics.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer and/or atypical antipsychotic, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period. Conditions: Bipolar Disorder I or II With a Major Depressive Episode Interventions: ALTO-100, Placebo Lead Sponsor: Alto Neuroscience Planned Enrollment: 200 participants